|
1
|
Ratziu V, Bellentani S, Cortez-Pinto H,
Day C and Marchesini G: A position statement on NAFLD/NASH based on
the EASL 2009 special conference. J Hepatol. 53:372–384. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cotter TG and Rinella M: Nonalcoholic
fatty liver disease 2020: The state of the disease.
Gastroenterology. 158:1851–1864. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balakrishnan M and Loomba R: The role of
noninvasive tests for differentiating NASH from NAFL and diagnosing
advanced fibrosis among patients with NAFLD. J Clin Gastroenterol.
54:107–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ludwig J, Viggiano TR, McGill DB and Oh
BJ: Nonalcoholic steatohepatitis: Mayo clinic experiences with a
hitherto unnamed disease. Mayo Clin Proc. 55:434–438.
1980.PubMed/NCBI
|
|
5
|
Matteoni CA, Younossi ZM, Gramlich T,
Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver
disease: A spectrum of clinical and pathological severity.
Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brunt EM, Janney CG, Di Bisceglie AM,
Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: A
proposal for grading and staging the histological lesions. Am J
Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang DQ, El-Serag HB and Loomba R: Global
epidemiology of NAFLD-related HCC: Trends, predictions, risk
factors and prevention. Nat Rev Gastroenterol Hepatol. 18:223–238.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Younossi Z, Tacke F, Arrese M, Chander
Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George
J, Fan J and Vos MB: Global perspectives on nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis. Hepatology.
69:2672–2682. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Argo CK, Northup PG, Al-Osaimi AM and
Caldwell SH: Systematic review of risk factors for fibrosis
progression in non-alcoholic steatohepatitis. J Hepatol.
51:371–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yatsuji S, Hashimoto E, Tobari M, Taniai
M, Tokushige K and Shiratori K: Clinical features and outcomes of
cirrhosis due to non-alcoholic steatohepatitis compared with
cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol.
24:248–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nagai K, Kohno K, Chiba M, Pak S, Murata
S, Fukunaga K, Kobayashi A, Yasue H and Ohkohchi N: Differential
expression profiles of sense and antisense transcripts between
HCV-associated hepatocellular carcinoma and corresponding
non-cancerous liver tissue. Int J Oncol. 40:1813–1820.
2012.PubMed/NCBI
|
|
12
|
Tan Y, Ge G, Pan T, Wen D and Gan J: A
pilot study of serum microRNAs panel as potential biomarkers for
diagnosis of nonalcoholic fatty liver disease. PLoS One.
9:e1051922014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsumoto M, Hada N, Sakamaki Y, Uno A,
Shiga T, Tanaka C, Ito T, Katsume A and Sudoh M: An improved mouse
model that rapidly develops fibrosis in non-alcoholic
steatohepatitis. Int J Exp Pathol. 94:93–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toita R and Kang JH: Long-term profile of
serological biomarkers, hepatic inflammation, and fibrosis in a
mouse model of non-alcoholic fatty liver disease. Toxicol Lett.
332:1–6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si
SY and Hong B: MicroRNAs 185, 96, and 223 repress selective
high-density lipoprotein cholesterol uptake through
posttranscriptional inhibition. Mol Cell Biol. 33:1956–1964. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qadir XV, Chen W, Han C, Song K, Zhang J
and Wu T: miR-223 deficiency protects against fas-induced
hepatocyte apoptosis and liver injury through targeting
insulin-like growth factor 1 receptor. Am J Pathol. 185:3141–3151.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Katsura A, Morishita A, Iwama H, Tani J,
Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, et al:
MicroRNA profiles following metformin treatment in a mouse model of
non-alcoholic steatohepatitis. Int J Mol Med. 35:877–884. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuivaniemi H and Tromp G: Type III
collagen (COL3A1): Gene and protein structure, tissue distribution,
and associated diseases. Gene. 707:151–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Y, He Y and Li J: MicroRNA-21: A
central regulator of fibrotic diseases via various targets. Curr
Pharm Des. 21:2236–2242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loyer X, Paradis V, Hénique C, Vion AC,
Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, et al:
Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis
and contributes to the disease in experimental models by inhibiting
PPARα expression. Gut. 65:1882–1894. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Becker PP, Rau M, Schmitt J, Malsch C,
Hammer C, Bantel H, Müllhaupt B and Geier A: Performance of serum
microRNAs −122, −192 and −21 as biomarkers in patients with
non-alcoholic steatohepatitis. PLoS One. 10:e01426612015.
View Article : Google Scholar : PubMed/NCBI
|
